195 related articles for article (PubMed ID: 30543869)
1. The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder.
Lee EJ; Lim YM; Kim SY; Lee J; Kim H; Jin JY; Oh YJ; Kim KK
J Neuroimmunol; 2019 Mar; 328():1-4. PubMed ID: 30543869
[TBL] [Abstract][Full Text] [Related]
2. Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica.
Masuda H; Mori M; Uzawa A; Muto M; Uchida T; Kuwabara S
Eur J Neurol; 2016 Feb; 23(2):276-81. PubMed ID: 25903772
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders.
Lin L; Hang H; Zhang J; Lu J; Chen D; Shi J
Mult Scler Relat Disord; 2022 Feb; 58():103494. PubMed ID: 35051897
[TBL] [Abstract][Full Text] [Related]
4. Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.
Wang R; Sun DR; Du Q; Zhang Y; Chen HX; Wang XF; Kong LY; Luo WQ; Shi ZY; Zhou HY
J Neuroimmunol; 2023 Sep; 382():578151. PubMed ID: 37453208
[TBL] [Abstract][Full Text] [Related]
5. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
[TBL] [Abstract][Full Text] [Related]
6. Time-Dependent Analysis of Sicca Symptoms and Anti-Ro/SSA and Anti-La/SSB Antibodies in Patients with AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T; Takahashi T; Misu T; Fujihara K; Nakashima I; Aoki M
Tohoku J Exp Med; 2023 Jul; 260(3):215-221. PubMed ID: 37081618
[TBL] [Abstract][Full Text] [Related]
7. Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder.
Fan R; Zhang Y; Xu Y; Tong J; Chen Z; Gu M; Fan W; Chen Y; Peng F; Jiang Y
Brain Behav; 2021 Jan; 11(1):e01865. PubMed ID: 33319460
[TBL] [Abstract][Full Text] [Related]
8. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica and non organ-specific autoimmunity.
Pittock SJ; Lennon VA; de Seze J; Vermersch P; Homburger HA; Wingerchuk DM; Lucchinetti CF; Zéphir H; Moder K; Weinshenker BG
Arch Neurol; 2008 Jan; 65(1):78-83. PubMed ID: 18195142
[TBL] [Abstract][Full Text] [Related]
11. Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica.
Pereira WLCJ; Reiche EMV; Kallaur AP; Oliveira SR; Simão ANC; Lozovoy MAB; Schiavão LJV; Rodrigues PRDVP; Alfieri DF; Flauzino T; Kaimen-Maciel DR
Acta Neuropsychiatr; 2017 Jun; 29(3):170-178. PubMed ID: 27692000
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
13. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
14. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
15. [Neuromyelitis optica and neuromyelitis optica spectrum disorders].
Simaniv TO; Vasiliev AV; Askarova LS; Zakharova MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):35-48. PubMed ID: 31934987
[TBL] [Abstract][Full Text] [Related]
16. Multiple Autoantibodies and Neuromyelitis Optica Spectrum Disorders.
Chen C; Xiaobo S; Yuge W; Yaqing S; Ling F; Lisheng P; Zhengqi L; Wei Q
Neuroimmunomodulation; 2016; 23(3):151-156. PubMed ID: 27603214
[TBL] [Abstract][Full Text] [Related]
17. Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.
Li H; Wang Y; Xu Q; Zhang A; Zhou H; Zhao S; Kang H; Peng C; Cao S; Wei S
J Neurol; 2015 Oct; 262(10):2293-304. PubMed ID: 26162715
[TBL] [Abstract][Full Text] [Related]
18. The association between dietary total antioxidant capacity and NMO-IgG seropositivity in patients with neuromyelitis optica spectrum disorder.
Rezaeimanesh N; Jahromi SR; Sahraian MA; Rafiee P; Moghadasi AN
Clin Neurol Neurosurg; 2021 Oct; 209():106903. PubMed ID: 34461362
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.
Banwell B; Tenembaum S; Lennon VA; Ursell E; Kennedy J; Bar-Or A; Weinshenker BG; Lucchinetti CF; Pittock SJ
Neurology; 2008 Jan; 70(5):344-52. PubMed ID: 18094334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
